Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMO: CC to announce they "need" to do some dilution to invest and increase (uhm, uhm) "revenues"
FDA miracle needed: If not: dilution, more liabilities, game over.
The product is good, the IR department is run like a Kindergarten, clinical research associates failed in their 510(k) filing, etc...
It's nice from the FDA to make time for talks. But nephros is just a small company which cannot put sufficient pressure to change the outcome nor can pressurize the FDA to speed up the time to clear/unclear the device.
Nephros SEEMS to be doomed to fall back under 0.10 dollar and to become a simple 'pump and dump' play. Unless this miracle happens
DM has 100B shares to dilute if he wants. That will take a long time. If they can get some kind of financing done and open one fuel station, we will get the short squeeze of the century.
AND THAT IS WHY THE PROBABILITY THAT THIS STOCK WILL RISE WITH 100% OR MORE IS HIGHER THAN THE PROBABILITY THAT THERE WILL BE A REVERSE SPLIT.
And that ladies and gentlemen is very bad news for people who are short on this company!
New news would be 510(k) clearance. Could be any day and is expected before the end of August.
Other news to be expected:
-- new partnerships
-- uplisting news
-- ..
That was old news
I don't expect much of it...
Now that the ATACCC conference is finished I expect some feedback from the company regarding the last 3 conferences (LSI and the 2 military ones).
WHY WOULD THEY DO A R:S? Think about it: they still have 100B authorised shares to throw in the market, so plenty enough to dilute. So I think there is no chance a r:s will be coming soon.
Imagine to wake up and watch this stock at 0.50dollar/share b/c of the FDA approval.
Sorry, I am using vantagewire and can only see level 2 with OTC not pinksheets.
q-report is out...
6th consecutive green candlestick, again with a higher volume than the 90day average volume. Lot's of potential to move higher: on a technical basis, but also with expectations around FDA clearance which can happen any day.
FDA clearance is way too close. People don't want to miss the train from this Wall Street Journal runner-up award winning company for innovation 2009.
It's because I've done some DD and noticed that there are already 5 green candlesticks on consecutive days.
I trust analysts more than you. And analysts say that BIEL will be worth 0.3-0.5 dollar/share when it's FDA cleared. FDA answer to be expected before the end of August.
This runner-up for the Wall Street Journal's innovation award could be a real dollarmine!
Remember FDA clearance= 0.3-0.5 dollar/share according to some analysts.
Remember: 60days are running out of time so 510(k) clearance can be any time now!
IMO we should hear FDA news before the end of August.
It could be today, tomorrow, but it should be before the end of August.
When the harvesting starts at the end of 2010 PPS will be above the 52wk high and that means above 0.070 dollar/share
75 patients enrolled: increase of enrollment rate expected:
"The Company has taken a number of steps to improve recruitment, the most significant of which is the increase in the number of our clinical trial sites. With more sites actively seeking to enroll patients, we expect the patient enrollment rate to continue to increase going forward.
Depending on the rate of enrollment, we expect to complete the patient enrollment between the second half of 2010 to the first quarter of 2011. Concurrent with the clinical study, we have commenced our preparation for the CE Mark approval process. Assuming availability of adequate and timely funding, a successful outcome of the study, and CE Mark regulatory approval, the Company intends to commercialize its product in Europe. "
10Q
Great news!
Q report was rather satisfying with almost zero increase in O/S.
1. company is undervalued... investors were afraid that O/S did increase big time through dilution, but instead the decrease in PPS was due to shorting and impatient shareholders
2. because the 90D average volume has been more than doubled today, I believe there is more upto than only an upwards pps correction. Possibilities:
-- FDA clearance
-- uplisting
-- institutional investments
-- more partnerships and distibutors
-- (buyout)
PS remember this analyst saying almost 1 year ago, that pps should be around 0.30 - 0.50 when the products were FDA cleared?
"When the 90 day average is 4.7 million, 11 million @ 1pm is heavy" quote Dreamcatcher.
FDA news?
Revenues were $466,864 for the six months ended June 30, 2010, as compared to revenues of $304,823 for the six months ended
June 30, 2009, and were comprised of licensing fees of approximately $100,000 for a Zindaclin® milestone and $46,000 for two OraDisc™ licensing agreements, $75,000 of foreign royalties from the sale of Zindaclin® by our distributor, $34,000 of domestic royalties from the sale of Aphthasol® by our distributor, and product sales of approximately $138,000 for Aphthasol® and $74,000 for Altrazeal®.
The six months ended June 30, 2010 revenues represent an overall increase of approximately $162,000 versus the comparative six
months ended June 30, 2009 revenues, due primarily to an increase of $138,000 in Aphthasol® product sales as we did not sell
any Aphthasol® finished product to our domestic distributor during the first quarter of 2009 and an increase of $100,000 in
licensing due to the achievement of a Zindaclin® milestone. These increases were partially offset by decreases in Zindaclin®
royalty fees of $25,000 and sponsored research of $32,000.
"Net cash provided by investing activities during the six months ended June 30, 2010 was $300,000 and relates to the proceeds
received in June 2010 from the divestiture of our Zindaclin® intangible asset. The Company expects to receive additional
payments from the divestiture of Zindaclin® of $250,000 by November 2010, $250,000 in June 2011, and $250,000 in June 2012."
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7417336
Very positive 10Q!!! Looking forward to CC.
Summary of the 10Q:
1. MOOOOORE revenues in the three months compared with the same three months in 2009; MOOOOORE revenues in the first half year of 2010 compared with the first half year in 2010.
2. Reduction in costs.
3. More than satisfying liquidity
??? IMO "that was all folks"
congrats to the daytraders here
great post
Name me one shop or store where they sell products of BIEL. I don't need the name of the distributor, because I can find that on their website.
They'll start harvesting algae in end 2010. It is mentioned in their Q-report. I think Biocin has enough patience for that, don't you think so...
CTSO: PRESENTATION AT RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE. September 12-15 2010
http://www.rodmanandrenshaw.com/conferences?id=51&link=presenters
CTSO: PRESENTATION AT RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE. September 12-15 2010
http://www.rodmanandrenshaw.com/conferences?id=51&link=presenters
Thanks Peter. Have a nice weekend and you know, if I find something new I'll report it here.
The autor of that article is long. How could you analyse BIEL on an objective way. Crazy!!! Seems like this autor is desperate himself, just as the CEO of Biel.
DUMP!!!
Behl is a starting company and will have given a better price.
By the way did you know that: "BioCentric Algae charges less than three hundred thousand dollars per acre to install Algae Pro Photobioreactor - Our nearest competitor charges well over eight hundred thousand dollars per acre."
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=35081 page 7
This is the moment investors come and watch, experts come and ask questions, press comes to cover their story, ...
This is real people!
Do they still have 4,568,253,327 shares outstanding? And almost 7billion shares authorised?
Is this still current what pinksheets says: http://www.otcmarkets.com/stock/CBAI/company-info
Thanks for the info.
"Depending upon the needs of our customers, we may have to increase our installation staff significantly in 2010 to ensure that installations can be completed while applicable rebates remain in effect. We expect that our selling and general and administrative expenses will increase in future periods as we expand our administrative, sales and installation workforce.
We outgrew our original offices and in June 2008 leased new office space in Mineola, New York as our headquarters which
can accommodate our expected needs for the next three years. See Lease Commitments in Note 7 in Item 1. Financial Statements. In
addition, we anticipate establishing regional field offices for our sales teams. Accordingly, we expect the rental expense component ofour general and administrative expenses to increase in future periods.
We expect our immediate capital expenditures, which we do not expect to exceed approximately $250,000, will be related to
completing the Beta tests and preparations for the initial launch of XTRAX ® , which includes being “listed” by Underwriters Laboratories and approved by the Federal Communications Commission and the various cellular telephone carriers over whose networks XTRAX ® would transmit the data it collects, through our majority owned subsidiary, Carbon 612. Subject to industry and governmental approvals, and availability of funds to us and to C612, we expect to be able to have a commercial XTRAX ® product during 2011; however, no assurance can be given that our expectations will be met. Cranes and other solar energy system installation equipment are generally available for rental on reasonable terms, and we do not have plans to acquire any.
Generally, we anticipate that our operating costs and expenses will increase in the future to support a higher level of
revenues. Increased costs will be attributable to increased personnel, principally sales and installation personnel and support staff for a multi-office infrastructure and increased marketing expenditures to promote our services."
+
"We also plan to expand to other locations where the amount of sunshine, the cost of electricity and/or the availability of governmental rebates make prospects of solar energy system sales appear attractive."
page 18-19:
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7414435
BINGOOOO
More than 1.4B shares. Not a single FDA approval. Distributers ok, but not a single store selling the products?
way oversold, watch out for this scam